PCMA: 'It Was Mistake for Mylan (MYL) to Adopt Pricing Strategy Used Unsuccessfully by Valeant (VRX), Turing'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand
August 29, 2016 6:06 AM EDTMylan N.V. (Nasdaq: MYL) announced that its U.S. subsidiary will launch the first generic to EpiPen Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"), of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton... More
Bill Ackman Says Valeant (VRX) Now 'Classic' Pershing Square Investment - CNBC
August 26, 2016 8:15 AM EDTBill Ackman says Valeant Pharma (NYSE: VRX) has made a lot of progress and that a passive position was a "mistake," according to commentary on CNBC today. The investor says Valeant is now a "classic" Pershing Square investment.
